Martin Lush, President of NSF Health Sciences Pharma Biotech, was invited by the organizers of Pharma Integrates to facilitate the panel discussion “Managing the Complexity Crisis with Productive Paranoia – Surviving in a Volatile Market World of Excessive Bureaucracy.” This popular event within the pharmaceutical industry took place on November 15–16 in London.

Driven by an aging population, globalization and urbanization, the level of change in the next five years will be greater than the pharmaceutical industry has experienced in the previous 35. A seismic shift is coming that will, for the unprepared, make existing three-to-five year plans redundant. Falling profit margins, greater operating costs, volatile demand forecasts, supply chain disruption, material and people shortages, etc. will have multiple repercussions, and only the resilient will survive. Those who are productively paranoid and have prepared their organizations to become resilient, adopted intelligent risk management and taken their overly complex legislation, systems and procedures back to basics will thrive and prosper.

The panel discussed what these challenges are and how the industry should prepare to meet them. Panelists included:

  • Gino Martini, Innovation and Outreach Lead, Roche Pharmaceuticals
  • Stephen Brewis, Chief Research Scientist, BT Innovate & Design
  • Martin Price, Vice President Health Economics, Market Access and Reimbursement, Janssen Europe, Middle East and Africa
  • Martin Gibson, Chief Executive Officer & Director, NWEH & Greater Manchester NIHR Clinical Research Network
  • Catherine Geyman, Director, Intersys